TrialsgrambetaRCTs are beautiful

INBUILD

2019

Nintedanib in Progressive Fibrosing Interstitial Lung Diseases

In 663 patients with non-IPF progressive fibrosing ILD, nintedanib slowed annual FVC decline compared with placebo.

Result

Primary endpoint: Annual rate of FVC decline

-80.8 vs -187.8 mL/year (difference 107 mL; p<0.001); effect consistent across UIP and non-UIP HRCT pattern.

Original publication
Subtopic
Progressive fibrosing ILD
Design
Multicentre RCT
Relevance
Important: one of several pillars.
Source
Flaherty KR, et al. N Engl J Med. 2019;381(18):1718-1727.doi 10.1056/NEJMoa1908681

Discussion & critique

Broadened nintedanib's indication beyond IPF to any progressive fibrosing ILD.

Discussed in podcasts